Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
AAV
MCID: ANC002
MIFTS: 44

Anca-Associated Vasculitis (AAV)

Categories: Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Anca-Associated Vasculitis

About this section

MalaCards integrated aliases for Anca-Associated Vasculitis:

Name: Anca-Associated Vasculitis 54
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 54 74
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 54
Aav 54

Classifications:

MalaCards categories:
Global: Rare diseases
See all MalaCards categories (disease lists)


External Ids:

UMLS 74 C2717865
Sources

Summaries for Anca-Associated Vasculitis

About this section
NIH Rare Diseases : 54 Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of diseases (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis), characterized by destruction and inflammation of small vessels. The clinical signs vary and affect several organs, such as the kidney, stomach, intestine, and lung. Skin lesions, such as purpura and urticaria, result when blood from small vessels leaks under the skin. AAV occurs when neutrophils attack small and medium vessels of the body. The underlying reason for this remains unclear. Treatment includes cyclophosphamide,  glucocorticoids and other autoimmune drugs such as rituximab. 

MalaCards based summary : Anca-Associated Vasculitis, also known as anti-neutrophil cytoplasmic antibody-associated vasculitis, is related to vasculitis and polyarteritis nodosa. An important gene associated with Anca-Associated Vasculitis is MPO (Myeloperoxidase), and among its related pathways/superpathways are Innate Immune System and Rheumatoid arthritis. The drugs alemtuzumab and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, lung and kidney.

Wikipedia : 77 Granulomatosis with polyangiitis (GPA), formerly known as Wegener''s Granulomatosis (WG), is a long-term... more...

Sources

Related Diseases for Anca-Associated Vasculitis

About this section

Diseases related to Anca-Associated Vasculitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 336)
# Related Disease Score Top Affiliating Genes
1 vasculitis 31.7 MPO PRTN3 SERPINA1 TNF
2 polyarteritis nodosa 30.6 MPO PRTN3
3 granulocytopenia 30.4 MPO TNF
4 rapidly progressive glomerulonephritis 30.4 MPO PRTN3
5 hyperthyroidism 30.0 CTLA4 GHRL PRTN3
6 cystic fibrosis 29.9 MPO PRTN3 SERPINA1
7 ulcerative colitis 29.9 MPO PRTN3 TNF
8 autoimmune disease 29.9 CTLA4 HLA-DRB1 TNF
9 lung disease 29.9 MPO PRTN3 SERPINA1 TNF
10 colitis 29.8 CTLA4 MPO TNF
11 granulomatosis with polyangiitis 29.7 CTLA4 HMGB1 MPO PRTN3 SERPINA1
12 mixed connective tissue disease 29.6 HLA-DRB1 TNF
13 microscopic polyangiitis 29.5 HLA-DRB1 MPO TNF
14 rheumatoid arthritis 29.4 CTLA4 HLA-DRB1 HMGB1 PRTN3 TNF
15 systemic lupus erythematosus 29.2 CTLA4 HLA-DRB1 HMGB1 MPO PRTN3 TNF
16 cholangitis 29.1 HLA-DRB1 PRTN3 TNF
17 glomerulonephritis 10.5
18 otitis media 10.4
19 aortitis 10.3
20 monoclonal paraproteinemia 10.3 MPO PRTN3
21 arthritis 10.3
22 influenza 10.3
23 chronic orbital inflammation 10.3 CTLA4 PRTN3
24 chronic maxillary sinusitis 10.3 MPO PRTN3
25 anterior scleritis 10.3 MPO PRTN3
26 pulmonary hemosiderosis 10.3 MPO PRTN3
27 lupus erythematosus 10.3
28 arteritic anterior ischemic optic neuropathy 10.3 MPO PRTN3
29 hemophilia b 10.3
30 muscular dystrophy 10.3
31 kawasaki disease 10.3
32 transient arthritis 10.3 PRTN3 SERPINA1
33 scleroderma, familial progressive 10.2
34 pulmonary fibrosis 10.2
35 pneumonia 10.2
36 diffuse alveolar hemorrhage 10.2
37 muscular dystrophy, duchenne type 10.2
38 glycogen storage disease 10.2
39 retinal degeneration 10.2
40 stroke, ischemic 10.2
41 hemorrhage, intracerebral 10.2
42 systemic scleroderma 10.2
43 respiratory failure 10.2
44 crescentic glomerulonephritis 10.2
45 interstitial lung disease 10.2
46 posterior scleritis 10.2 PRTN3 TNF
47 autoimmune inner ear disease 10.2 MPO TNF
48 inner ear disease 10.2 MPO TNF
49 hemophilia a 10.2
50 achromatopsia 10.2

Graphical network of the top 20 diseases related to Anca-Associated Vasculitis:



Diseases related to Anca-Associated Vasculitis
Sources

Symptoms & Phenotypes for Anca-Associated Vasculitis

About this section
Sources

Drugs & Therapeutics for Anca-Associated Vasculitis

About this section

Drugs for Anca-Associated Vasculitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
3
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 446-86-6 2265
4
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 83-43-2 6741
5
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Not Applicable 2921-57-5
6
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 53-03-2 5865
7
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 302-25-0
8
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 50-24-8 5755
9
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
10
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
11
leucovorin Approved Phase 4,Phase 3,Phase 2 58-05-9 6006 143
12
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
13
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
14
Prednisolone hemisuccinate Experimental Phase 4,Phase 2,Phase 3,Not Applicable 2920-86-7
15 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Alkylating Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Not Applicable
23 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Not Applicable
24 Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
25 Methylprednisolone Acetate Phase 4,Phase 2,Phase 3,Not Applicable
26 glucocorticoids Phase 4,Phase 2,Phase 3,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Not Applicable
28 Hormones Phase 4,Phase 2,Phase 3,Not Applicable
29 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Not Applicable
30 Prednisolone acetate Phase 4,Phase 2,Phase 3,Not Applicable
31 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
33 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
34 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B Complex Phase 4,Phase 3,Phase 2
36 Protective Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
38 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Not Applicable
39 Neuroprotective Agents Phase 4,Phase 2,Phase 3,Not Applicable
40 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
41 Folate Phase 4,Phase 3,Phase 2
42 Antiemetics Phase 4,Phase 2,Phase 3,Not Applicable
43 Antitubercular Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Vitamin B9 Phase 4,Phase 3,Phase 2
45 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
46 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Antibodies Phase 4,Phase 2,Phase 3,Not Applicable
48 Antibodies, Antineutrophil Cytoplasmic Phase 4,Phase 3,Phase 2,Not Applicable
49 Immunoglobulins Phase 4,Phase 2,Phase 3,Not Applicable
50 Tin Fluorides Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Alemtuzumab for ANCA Associated Refractory Vasculitis Unknown status NCT01405807 Phase 4 Alemtuzumab
2 CHUSPAN SCS BP Treatment of Churg–Strauss Syndrome Without Poor-Prognosis Factors Unknown status NCT00399399 Phase 4 azathioprine;cyclophosphamide
3 CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors Unknown status NCT00400075 Phase 4 azathioprine;cyclophosphamide
4 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Completed NCT02169219 Phase 4 Glucocorticoids;Rituximab
5 Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Completed NCT00307671 Phase 4 prednisone, methylprednisolone,cyclophosphamides;Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Mycophenolate mofetil,methotrexate
6 Low-dose Glucocorticoid Vasculitis Induction Study Recruiting NCT02198248 Phase 4 Rituximab;Glucocorticoids
7 Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Recruiting NCT02749292 Phase 4 Rituximab
8 A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis Recruiting NCT02115997 Phase 4 Methylprednisolone;Prednisone;Rituximab
9 Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Recruiting NCT03164473 Phase 4 Rituximab;Azathioprine;Placebo-rituximab;Placebo-azathioprine
10 Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis Terminated NCT00128895 Phase 4 azathioprine
11 Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis Terminated NCT02626845 Phase 4 Rituximab
12 Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Terminated NCT00747461 Phase 4
13 WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides Unknown status NCT00349674 Phase 3 Azathioprine: 2 mg/kg/day;methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
14 Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA) Unknown status NCT00103792 Phase 3 mycophenolate mofetil;cyclophosphamide
15 Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery Unknown status NCT01297959 Phase 3 E-101 Solution 300 GU/ml;Saline solution
16 Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Completed NCT01731561 Phase 3 Rituximab (Arm B);Rituximab (Arm A)
17 Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Completed NCT00430105 Phase 2, Phase 3 cyclophosphamide
18 Efficacy Study of Two Treatments in the Remission of Vasculitis Completed NCT00748644 Phase 3 Rituximab;Azathioprine
19 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis Completed NCT00104299 Phase 2, Phase 3 Rituximab plus cyclophosphamide placebo (rituximab group);Cyclophosphamide plus rituximab placebo (control group);Azathioprine;Methylprednisolone (or other glucocorticoid);Prednisone
20 Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis Completed NCT00414128 Phase 2, Phase 3 mycophenolate mofetil;cyclophosphamide
21 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Completed NCT00987389 Phase 3 Glucocorticoids
22 A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis Completed NCT02020889 Phase 3 Placebo
23 Belimumab in Remission of VASculitis Completed NCT01663623 Phase 3 Azathioprine
24 Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Completed NCT00647166 Phase 3 corticosteroid and azathioprine;corticosteroid and placebo
25 Etanercept for Wegener's Granulomatosis Completed NCT00005007 Phase 2, Phase 3 Etanercept
26 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
27 Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease Recruiting NCT03323476 Phase 3 Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®
28 Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) Recruiting NCT02108860 Phase 3 Abatacept;placebo
29 The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach Recruiting NCT01933724 Phase 3 5 mg prednisone;0 mg prednisone
30 The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach Recruiting NCT01940094 Phase 3 5 mg Prednisone;0 mg Prednisone
31 Rituximab in Eosinophilic Granulomatosis With Polyangiitis Recruiting NCT02807103 Phase 3 Rituximab;Placebo-rituximab;Cyclophosphamide;Placebo-cyclophosphamide
32 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Active, not recruiting NCT02994927 Phase 3 CCX168;Prednisone;Cyclophosphamide;Azathioprine
33 Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab Active, not recruiting NCT02433522 Phase 3 rituximab;Placebo
34 Rituximab Vasculitis Maintenance Study Active, not recruiting NCT01697267 Phase 3 Azathioprine
35 Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921 Active, not recruiting NCT03298061 Phase 3 Mepolizumab;Prednisolone
36 The Effect of Some Drugs Used in Treatment of Vasculitis on the Complement System in Children Not yet recruiting NCT03692416 Phase 3 Ibuprofen;Prednisone;Methotrexate
37 IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis Terminated NCT00307645 Phase 3 Cyclophosphamide;Mycophenolate mofetil;Azathioprine;Prednisone (and methylprednisolone)
38 Intravenous Immunoglobulin After Relapse in Vasculitis Terminated NCT00307658 Phase 3 Intravenous immunoglobulins (human immunoglobulins G)
39 Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis Terminated NCT01446211 Phase 3 Gusperimus + glucocorticoids;cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
40 Plasma Exchange for Renal Vasculitis Terminated NCT01408836 Phase 2, Phase 3 Intravenous methyl prednisolone;Methyl prednisolone
41 CMV Modulation of the Immune System in ANCA-associated Vasculitis Unknown status NCT01633476 Phase 2 Valaciclovir
42 Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Unknown status NCT00751517 Phase 2 Methotrexate;Cyclophosphamide
43 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis Completed NCT02222155 Phase 2 CCX168 low dose plus standard of care;CCX168 high dose plus standard of care
44 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis Completed NCT01363388 Phase 2 Placebo;CCX168
45 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Completed NCT00293072 Phase 2 Rituximab
46 Anti-Cytokine Therapy for Vasculitis Completed NCT00753103 Phase 2 Cyclophosphamide;Prednisolone;Azathioprine;Mycophenolate mofetil;Methylprednisolone
47 Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome Completed NCT00716651 Phase 2 mepolizumab
48 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome Completed NCT00527566 Phase 1, Phase 2
49 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis Completed NCT00530075 Phase 2 Gusperimus
50 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis Completed NCT01750697 Phase 2 Rituximab

Search NIH Clinical Center for Anca-Associated Vasculitis

Sources

Genetic Tests for Anca-Associated Vasculitis

About this section
Sources

Anatomical Context for Anca-Associated Vasculitis

About this section

MalaCards organs/tissues related to Anca-Associated Vasculitis:

42
Neutrophil, Lung, Kidney, Skin, Heart, Eye, T Cells
Sources

Publications for Anca-Associated Vasculitis

About this section

Articles related to Anca-Associated Vasculitis:

(show top 50) (show all 811)
# Title Authors Year
1
Clinical impact of alpha-1-antitrypsin deficiency in ANCA-associated vasculitis: results from a French retrospective monocentric cohort of 142 consecutive patients. ( 30824651 )
2019
2
Updating OMERACT Core Set of Domains for ANCA-Associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability and Health. ( 30709951 )
2019
3
Prognostic nutritional index is associated with disease severity and relapse in ANCA-associated vasculitis. ( 30729693 )
2019
4
Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4-related diseases: case series and review of literature. ( 30734199 )
2019
5
Changing landscape of immunosuppression in ANCA-associated vasculitis. ( 30755415 )
2019
6
Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort. ( 30767717 )
2019
7
Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study. ( 30777023 )
2019
8
Persistent antiphospholipid antibodies are associated with thrombotic events in ANCA-associated vasculitis: A retrospective monocentric study. ( 30798998 )
2019
9
Clinical impact of subgrouping ANCA-associated vasculitis according to antibody specificity beyond the clinicopathological classification. ( 30805643 )
2019
10
Diffuse alveolar hemorrhage in a patient with ANCA-associated vasculitis after thyroidectomy: A case report. ( 30813199 )
2019
11
Immunoglobulins G from patients with ANCA-associated vasculitis are atypically glycosylated in both the Fc and Fab regions and the relation to disease activity. ( 30818380 )
2019
12
MYCYC: unravelling the long road ahead in ANCA-associated vasculitis. ( 30894345 )
2019
13
Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis. ( 30896460 )
2019
14
Clinical and histopathological prognostic factors affecting the renal outcomes in childhood ANCA-associated vasculitis. ( 30607566 )
2019
15
Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. ( 30612116 )
2019
16
Hypertrophic pachymeningitis and cerebral venous thrombosis in myeloperoxidase-ANCA associated vasculitis. ( 30635307 )
2019
17
Author Correction: Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. ( 30655606 )
2019
18
Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Study. ( 30666823 )
2019
19
Low-dose rituximab as induction therapy for ANCA-associated vasculitis. ( 30680533 )
2019
20
Testicular granulomatous vasculitis mimicking testicular torsion in an anti-neutrophil cytoplasmic antibody-associated vasculitis patient. ( 30719308 )
2019
21
Platelets release proinflammatory microparticles in anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30843591 )
2019
22
Eosinophils in anti-neutrophil cytoplasmic antibody associated vasculitis. ( 30886997 )
2019
23
Response to: 'MYCYC, unravelling the long road ahead in ANCA-associated vasculitis' by Jain et al. ( 30894344 )
2019
24
Citrullinated histone H3 expression in anti-neutrophil cytoplasmic antibody-associated vasculitis in older Japanese autopsy patients. ( 30623538 )
2019
25
The formation and disordered degradation of neutrophil extracellular traps in necrotizing lesions of anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30677396 )
2019
26
Azathioprine hypersensitivity syndrome in anti-myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis. ( 30746133 )
2019
27
An Autopsy Case of Myeloperoxidase-anti-neutrophil Cytoplasmic Antibody (MPO-ANCA) -associated Vasculitis Accompanied by Cryoglobulinemic Vasculitis Affecting the Kidneys, Skin, and Gastrointestinal Tract. ( 29709950 )
2018
28
The adenosinergic system: a potential player in the pathogenesis of ANCA-associated vasculitis? ( 29745882 )
2018
29
Letter to the Editor: Time for cost-effectiveness studies for preventive strategies applied according to risk of cytomegalovirus-related morbidity and mortality in ANCA-associated vasculitis. ( 29663157 )
2018
30
Anti-neutrophil extracellular trap antibody in a patient with relapse of anti-neutrophil cytoplasmic antibody-associated vasculitis: a case report. ( 29929470 )
2018
31
The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis. ( 29885746 )
2018
32
Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA. ( 29606398 )
2018
33
Myeloperoxidase-ANCA-positive granulomatosis with polyangiitis is a distinct subset of ANCA-associated vasculitis: A retrospective analysis of 455 patients from a single center in China. ( 29887327 )
2018
34
Sweet's Syndrome Mimicking ANCA-Associated Vasculitis. ( 29355513 )
2018
35
PR3-ANCA: a potential biomarker of disease activity for propylthiouracil-induced ANCA-associated vasculitis. ( 29888703 )
2018
36
Cocaine and ANCA associated vasculitis-like syndromes - A case series. ( 29108823 )
2018
37
The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. ( 29371340 )
2018
38
Avacopan in the treatment of ANCA-associated vasculitis. ( 29718732 )
2018
39
Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. ( 29808456 )
2018
40
Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. ( 29695498 )
2018
41
Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis. ( 29611402 )
2018
42
ANCA associated vasculitis in patients from Saudi Arabia. ( 29643885 )
2018
43
ANCA-associated Vasculitis in a Case of Congenital Leptin Deficiency. ( 29937567 )
2018
44
Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. ( 29379322 )
2018
45
Correction to: Late-onset Pneumocystis jirovecii pneumonia (PJP) in patients with ANCA-associated vasculitis. ( 29971582 )
2018
46
Correction: Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial. ( 29358455 )
2018
47
Methimazole-induced ANCA-associated vasculitis with diffuse alveolar haemorrhage. ( 29760925 )
2018
48
Rituximab induction therapy for de novo ANCA associated vasculitis in pregnancy: a case report. ( 29954345 )
2018
49
Rituximab in ANCA-associated vasculitis: fewer infusions or ultra low-dose maintenance therapy? ( 29921573 )
2018
50
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). ( 29695500 )
2018
Sources

Variations for Anca-Associated Vasculitis

About this section
Sources

Expression for Anca-Associated Vasculitis

About this section
Search GEO for disease gene expression data for Anca-Associated Vasculitis.
Sources

Pathways for Anca-Associated Vasculitis

About this section

Pathways related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.51 CTLA4 HLA-DRB1 HMGB1 MPO PRTN3 SERPINA1
2
Rheumatoid arthritis 38
11.09 CTLA4 HLA-DRB1 TNF
3
Cytokines and Inflammatory Response 1
10.78 HLA-DRB1 TNF
4
Platinum Pathway, Pharmacokinetics/Pharmacodynamics 62
10.72 HMGB1 MPO
5
amb2 Integrin signaling 1
10.48 HMGB1 MPO TNF
6
LDL Oxidation in Atherogenesis 65
10.36 MPO TNF
Sources

GO Terms for Anca-Associated Vasculitis

About this section

Cellular components related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 ANGPT2 GHRL HMGB1 MPO PRTN3 SERPINA1
2 extracellular space GO:0005615 9.17 ANGPT2 GHRL HMGB1 MPO PRTN3 SERPINA1

Biological processes related to Anca-Associated Vasculitis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.51 HMGB1 TNF
2 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043280 9.49 HMGB1 TNF
3 negative regulation of blood vessel endothelial cell migration GO:0043537 9.48 ANGPT2 HMGB1
4 negative regulation of T cell proliferation GO:0042130 9.46 CTLA4 HLA-DRB1
5 neutrophil degranulation GO:0043312 9.46 HMGB1 MPO PRTN3 SERPINA1
6 negative regulation of endothelial cell proliferation GO:0001937 9.43 GHRL TNF
7 positive regulation of insulin secretion involved in cellular response to glucose stimulus GO:0035774 9.4 GHRL HLA-DRB1
8 negative regulation of interferon-gamma production GO:0032689 9.37 HLA-DRB1 HMGB1
9 positive regulation of vascular endothelial cell proliferation GO:1905564 9.26 GHRL HMGB1
10 positive regulation of sprouting angiogenesis GO:1903672 9.02 GHRL
11 negative regulation of growth of symbiont in host GO:0044130 8.96 MPO TNF
12 inflammatory response to antigenic stimulus GO:0002437 8.62 HLA-DRB1 HMGB1
Sources

Sources for Anca-Associated Vasculitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....